Adaptive Biotechnologies Corp. (ADPT)
27.57
-0.48
(-1.71%)
USD |
NASDAQ |
Nov 20, 10:47
Adaptive Biotechnologies Cash from Investing (Quarterly) : -125.06M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -125.06M |
| June 30, 2026 | -43.48M |
| March 31, 2026 | 9.143M |
| December 31, 2025 | -8.252M |
| September 30, 2025 | 17.28M |
| June 30, 2025 | 3.346M |
| March 31, 2025 | 25.57M |
| December 31, 2024 | 22.12M |
| September 30, 2024 | 5.287M |
| June 30, 2024 | 5.877M |
| March 31, 2024 | 44.51M |
| December 31, 2023 | 3.207M |
| September 30, 2023 | 26.14M |
| June 30, 2023 | 37.32M |
| March 31, 2023 | 62.98M |
| December 31, 2022 | -97.54M |
| September 30, 2022 | 58.02M |
| June 30, 2022 | 4.746M |
| Date | Value |
|---|---|
| March 31, 2022 | 37.69M |
| December 31, 2021 | 67.21M |
| September 30, 2021 | -21.27M |
| June 30, 2021 | 41.45M |
| March 31, 2021 | 93.82M |
| December 31, 2020 | -340.05M |
| September 30, 2020 | -97.25M |
| June 30, 2020 | 177.49M |
| March 31, 2020 | 142.76M |
| December 31, 2019 | 46.68M |
| September 30, 2019 | -260.85M |
| June 30, 2019 | -45.35M |
| March 31, 2019 | -222.18M |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | 4.662M |
| March 31, 2018 | -36.69M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Champions Oncology, Inc. | -0.055M |
| Medpace Holdings, Inc. | -20.14M |
| Avantor, Inc. | -38.50M |
| Personalis, Inc. | 24.01M |
| 10X Genomics, Inc. | -0.503M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 9.605M |
| Cash from Financing (Quarterly) | 21.17M |
| Free Cash Flow | -8.822M |
| Free Cash Flow Per Share (Quarterly) | 0.0411 |
| Free Cash Flow to Equity (Quarterly) | 9.204M |
| Free Cash Flow to Firm (Quarterly) | 8.179M |
| Free Cash Flow Yield | -0.20% |